Bromocriptine
As of the edition of 20 October 2026, Bromocriptine is a small molecule: marketed, first approved in 1979 (ES); acts on DRD2, DRD3 and DRD4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Parlodel
- First approved
- 1 May 1979 (ES)
- Approvals on record
- 5 in 3 regions
- Holder of the most recent approval
- VeroScience; 4 holders in all
- Registered trials
- 26, 1 stopped early
- Disease areas
- Nutrition and metabolism; Hormones; Nervous system; Heart and blood vessels; Mental health; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Bromocriptine.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 3 | 0 | 0 |
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 4 | 3 | 0 | 0 |
| Phase 3 | 8 | 4 | 0 | 0 |
| Phase 4 | 5 | 2 | 1 | 1 |
| All trials | 26 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| VeroScience | Later holder and Lead sponsor of trials | 2004 to now |
| Esjay Pharma | Acquired holder | 2024 to now |
| Novartis | Earlier holder |